MPWT
LGND icon

MassMutual Private Wealth & Trust’s Ligand Pharmaceuticals LGND Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Sell
117
-7
-6% -$1.65K ﹤0.01% 892
2026
Q1 		$24.8K Sell
124
-26
-17% -$5.14K ﹤0.01% 1014
2025
Q4 		$28.4K Buy
150
+6
+4% +$1.15K ﹤0.01% 980
2025
Q3 		$25.5K Hold
144
– – ﹤0.01% 1016
2025
Q2 		$16.4K Buy
144
+18
+14% +$1.92K ﹤0.01% 1178
2025
Q1 		$13.2K Buy
126
+40
+47% +$4.52K ﹤0.01% 1188
2024
Q4 		$9.21K Hold
86
– – ﹤0.01% 1289
2024
Q3 		$8.61K Hold
86
– – ﹤0.01% 1176
2024
Q2 		$7.25K Hold
86
– – ﹤0.01% 1190
2024
Q1 		$6.29K Hold
86
– – ﹤0.01% 1189
2023
Q4 		$6.14K Buy
+86
New +$5.08K ﹤0.01% 1178
2023
Q3 		– Sell
-13
Closed -$937 – 2006
2023
Q2 		$937 Hold
13
– – ﹤0.01% 1674
2023
Q1 		$956 Buy
+13
New +$924 ﹤0.01% 1589
2022
Q4 		– Sell
-26
Closed -$1K – 1758
2022
Q3 		$1K Buy
+26
New +$1.53K ﹤0.01% 1456
2019
Q4 		– Sell
-6,176
Closed -$384K – 848
2019
Q3 		$384K Sell
6,176
-202
-3% -$12.7K 0.03% 292
2019
Q2 		$454K Buy
6,378
+6,089
+2,107% +$448K 0.03% 268
2019
Q1 		$22.6K Sell
289
-49
-14% -$3.71K ﹤0.01% 502
2018
Q4 		$28.6K Sell
338
-27
-7% -$2.88K ﹤0.01% 453
2018
Q3 		$62.6K Sell
365
-4,034
-92% -$608K ﹤0.01% 406
2018
Q2 		$568K Buy
4,399
+244
+6% +$27.2K 0.05% 236
2018
Q1 		$428K Buy
4,155
+660
+19% +$65.3K 0.04% 253
2017
Q4 		$299K Buy
3,495
+93
+3% +$8.06K 0.02% 304
2017
Q3 		$289K Buy
3,402
+150
+5% +$11.9K 0.02% 317
2017
Q2 		$246K Buy
+3,252
New +$227K 0.02% 314

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

MassMutual Private Wealth & Trust's LGND Position: Q2 2026 in Review

MassMutual Private Wealth & Trust reduced its Ligand Pharmaceuticals (LGND) stake by 5.6% in Q2 2026, selling an estimated $1.65K and leaving 117 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

MassMutual Private Wealth & Trust first reported a position in LGND in Q2 2017 and has held it in 24 quarters since. The position peaked at $568K in Q2 2018. 144 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • MassMutual Private Wealth & Trust held 117 shares of Ligand Pharmaceuticals worth $37K as of Q2 2026.
  • MassMutual Private Wealth & Trust sold 7 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.65K.
  • Ligand Pharmaceuticals made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #892 holding.
  • MassMutual Private Wealth & Trust first reported a position in Ligand Pharmaceuticals in Q2 2017 and has held it in 24 quarters since.
  • MassMutual Private Wealth & Trust's Ligand Pharmaceuticals position peaked at $568K in Q2 2018.
  • 144 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.